IRLAB: Invitation to the year-end report 2025 presentation and webcast
Gothenburg, Sweden, February 18, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will hold a presentation in conjunction with the publication of the year-end report for 2025. The interim report will be published on Wednesday, February 25, 2026, at 07:00 CET.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
Q&A session with Kristina Torfgård, CEO and Nicholas Waters, EVP, Head of R&D, at Redeye Technology & Life Science Day
Kristina Torfgård, CEO, and Nicholas Waters, EVP, Head of R&D, participated in the Redeye Technology & Life Science Day on December 3, 2025. https://www.redeye.se/video/event-presentation/1130614/irlab-therapeuti%E2%80%A6-2025-october-15?embed
Read More >